ENOSF1基因多态性预测结直肠癌患者卡培他滨治疗安全性

表4 SNP显性、隐性模型与不良反应之间的关系

不良反应SNP	HFS		腹泻		中性粒细胞减少
	P值	OR (95%CI)	P值	OR (95%CI)	P值	OR (95%CI)
显性模型
rs2612091	0.311	0.536 (0.159-1.804)	0.215	2.500 (0.573-10.914)	0.762	0.832 (0.253-2.739)
IVS10-61C>T	0.085	0.344 (0.101-1.178)	0.817	0.842 (0.196-3.615)	0.130	0.404 (0.123-1.321)
IVS10-60G>A	0.020	4.364 (1.217-15.641)	0.331	2.105 (0.460-9.640)	0.353	1.731 (0.541-5.536)
rs1059394	0.672	0.787 (0.259-2.389)	0.402	1.667 (0.502-5.531)	0.373	0.618 (0.213-1.787)
隐性模型
rs2612091	1.000	0.583 (0.056-6.086)	1.000	1.257 (1.082-1.460)	1.000	0.692 (0.089-5.378)
IVS10-61C>T	0.643	0.422 (0.043-4.112)	0.039	0.108 (0.015-0.788)	0.385	3.167 (0.326-30.727)
IVS10-60G>A	0.167	4.462 (0.724-27.511)	1.000	1.176 (0.120-11.513)	1.000	1.500 (0.247-9.111)
rs1059394	1.000	0.804 (0.078-8.285)	0.566	1.318 (1.140-1.524)	0.637	0.611 (0.080-4.655)

SNP: 单核苷酸多态位点; HFS: 手足综合征.